|Description||QL47 is a potent and selective BTK inhibitor, which covalently modifies Cys481. QL47 inhibits BTK kinase activity with an IC50 of 7 nM, inhibits autophosphorylation of BTK on Tyr223 in cells with an EC50 of 475 nM and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr759) with an EC50 of 318 nM. In Ramos cells QL47 induces a G1 cell cycle arrest which is associated with pronounced degradation of BTK protein. QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concentrations.|
|Appearance||white solid powder|
|Synonyms||QL47; QL 47; QL47. QL-XII-47|
Btk inhibitor 1 R enantiomer
Btk inhibitor 1 R enantiomer is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplas...
RN486 is a reversible Bruton's tyrosine kinase (Btk) inhibitor with IC50 value of 4.0 nM.
PCI-32765 Racemate is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK), modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, ...
ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.
CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exqui...
ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Ph...
RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an ...